Opinion|Videos|December 12, 2025
Cumulative LDL-C Exposure
Panelists discuss how long-term LDL-C exposure heightens cardiovascular risk, making early and sustained lowering crucial.
Advertisement
Episodes in this series
Panelists discuss how cumulative low-density lipoprotein cholesterol (LDL-C) exposure compounds cardiovascular risk over time, underscoring the importance of early and sustained lowering. The “lower for longer” approach correlates strongly with reduced event rates.
They explain that each year of uncontrolled LDL-C contributes to plaque progression and irreversible vascular damage.
Panelists advocate for earlier initiation of therapy, proactive intensification, and lifelong adherence to minimize cumulative exposure.
Advertisement
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
2
Precision Drugs Meet Payer Realities
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
5